

HAI/AR Annual Progress Report: 2019 – 2020

Nijika Shrivastwa, PhD
EVALUATION UNIT, FIELD SUPPORT TEAM,
PREVENTION AND RESPONSE BRANCH, DIVISION OF HEALTHCARE QUALITY PROMOTION

Overview

☐ Summary of Performance Measures 2019 – 2020

- Containment Responses to Novel or Target MDROs
- Other HAI/AR Outbreak Responses
- COVID-19 Outbreaks and Response Consultations in Healthcare Settings
- Prevention-based Healthcare Infection Control Assessments
- Staff Capacity to Conduct Infection Control Assessments

☐ Jurisdiction Specific Report Template

HAI/AR PROGRAMS

2019–20 Progress Report

Period of Performance: August 1, 2019 – July 31, 2020
(Year 1 of the Current 5-Year ELC Cycle)

CDC/DDID/NCEZID/DHQP

Table of Contents

List of Tables and Figures	3
Executive Summary	6
National View of HAI/AR Programs: Overview & Background	8
Overview of HAI/AR Program Evaluation Framework at the National Level	9
HAI/AR Program (ELC) Performance Measures At-A-Glance	10
Year 1 Progress Details	11
I. SURVEILLANCE, DETECTION AND RESPONSE	11
1. Engagement with Clinical Laboratories	11
2. Containment Responses to Novel or Target MDROs	12
3. Other HAI Outbreak Response Activities (non-AR Containment)	16
4. COVID-19 Outbreaks and Responses in Healthcare Settings	19
II. PREVENTION AND INTERVENTION STRATEGIES	21
5. Prevention-based Onsite Infection Control Assessments (Non-COVID-19)	21
6. Prevention-based Healthcare Infection Control Assessments for COVID-19	24
7. Antibiotic Stewardship in Healthcare Facilities	25
8. Staff Capacity to Conduct Infection Control Assessments	29
III. COMMUNICATIONS, COORDINATION AND PARTNERSHIPS	32
9. Health Department HAI/AR Program Plans	32
10. Health Department Healthcare Setting Inventories	33
Conclusions	34
APPENDIX I: ELC HAI/AR Logic Model, 2019–2024 Strategy	35
Appendix II: Additional Detail on Calculation of AR Containment responses and AR consultations	36
Appendix III: List of Acronyms	37

HAI/AR Programs Progress Report 2019–2020

Includes:

- G1 (Epi) component of ELC performance measures
 - Reporting period August 1, 2019 – July 31, 2020
- Healthcare IPC COVID performance measures
 - Reporting period January 1, 2020 – July 31, 2020

Does not include:

- G2 (Lab) component of ELC
- Project Firstline

HAI/AR Programs Progress Report 2019–2020

This summary report provides an overview of how each recipient has progressed in implementing their HAI/AR programs.

The focus of this report is programmatic, not intended to demonstrate outcome and impact on eliminating HAIs.

Complimentary to the annual *National and State Healthcare-Associated Infections (HAI) Progress Report*

National View of HAI/AR Programs: Overview & Background

- ***DHQP invested in core epidemiology, infection prevention, and antibiotic stewardship funding (2019-2020)***
 - \$33.5 million (G1)
 - Awarded to 59 HAI/AR Programs
- ***Supplemental funding: 2020***
 - CARES and Enhancing Detection as part of the COVID-19 pandemic response was
 - Awarded to 64 jurisdictions
- ***Performance measures are reported by recipients using a standardized form in REDCap***
 - G1 – 7 performance measures
 - Healthcare IPC COVID – 3 performance measures

ELC HAI/AR Performance Measures At-A- Glance

Table 1: Summary of HAI/AR
Performance Measures

Performance Measure (PM) at the National Level Reported by 57 HAI/AR Programs in all 50 states and 7 local or territorial health departments (Chicago, District of Columbia, Houston, Los Angeles, New York City, Philadelphia, Puerto Rico)		Reporting Period August 2019 – July 2020	Reporting Period August 2020 – December 2020
Surveillance, Detection and Response			
PM1	Number of clinical laboratories engaged ⁴ to improve testing	2,372	N/A
PM2 ⁵	Number of AR Containment Responses ⁶ or AR Consultations ⁷ for novel or target MDROs	3,860	1,340
	Number of AR Containment Responses to novel or targeted MDROs (includes onsite infection control assessment and/or colonization screening)	423	133
	Number of AR Consultations to novel or targeted MDROs (involves remote assistance by the recipient without any onsite infection control assessment or colonization screening)	3,437	1,207
PM3 ⁵	Number of other HAI/AR (non-AR Containment) responses <i>COVID-19 response reported separately; see E25 below</i>	454	83
Prevention and Intervention Strategies			
PM4 ⁵	Number of prevention-based onsite infection control assessments. <i>COVID-19 activities reported separately; see E24 below</i>	549	52
PM5 ⁵	Number of facilities engaged to implement antibiotic stewardship	3,541	3,704
Communication, Coordination and Partnerships			
PM6	Number of HDs that updated their HAI/AR plans	8	N/A
PM7	Number of HDs that updated their healthcare settings inventories within the past year	47	N/A
COVID-19 Healthcare IPC Measures			
E23 ⁸	Number of HD staff who can independently perform healthcare infection control assessments (remote or onsite)	415 ⁸	681
E24 ^{5,8}	Number of prevention-based healthcare infection control assessments for COVID-19	5,689 ⁸	3,184
E25 ^{5,8}	Number of COVID-19 outbreaks and responses in healthcare settings		
	Number of possible COVID-19 outbreaks that met threshold for additional investigation	18,308 ⁸	34,991
	Of the possible COVID-19 outbreaks, number for which response consultation was provided	14,259 ⁸	24,825

*Performance Measure
(PM2): Containment
Responses to Novel or
Target MDROs*

Table 2: AR Containment Responses
and AR Consultations by Type, August
1, 2019 – July 31, 2020

Type of AR Response	Number of Responses (August 1, 2019 – July 31, 2020)
AR Containment Response (includes onsite infection control assessment and/or colonization screening)	423
AR Consultations (involves remote assistance by the HD without any onsite infection control assessment or colonization screening)	3,437
Total	3,860

Performance Measure (PM2): Containment Responses to Novel or Target MDROs

Table 3: AR Containment Responses and AR Consultations by Setting Type, August 1, 2019 – July 31, 2020

<i>Setting Type</i>	<i>Percentage Involving Screening and/or Onsite Assessment, by Setting</i>
	Percentage
Acute Care Hospital	11%
SNF	25%
LTACH	27%
vSNF	25%
Outpatient Setting	7%
Other	10%

Other HAI/AR Responses (non-AR Containment)

Table 7: Overall Number of COVID-19, Other HAI/AR Responses, and Routine HAI Response Consultations (N=20,976), August 1, 2019 – July 31, 2020

Other HAI/AR Responses	No. of responses
Other HAI/AR Responses (Non-COVID, Non-AR Containment) (Aug 1, 2019 – July 31, 2020)	454
COVID-19 responses (January 1, 2020 – July 31, 2020)	14,259
Total	14,713

Performance Measure (PM3): Other HAI/AR Responses (non-AR Containment)

Table 8: Distribution of Other HAI/AR Responses (N=454) by Event Type, August 1, 2019 – July 31, 2020

Event Type	Number of Events	Event Distribution (Number of Events/ Total Number of Responses)
Case, Cluster, or Outbreak Responses	343	76%
Serious Infection Control Breaches		
Reprocessing Breach	47	10%
Injection Safety Breach	36	8%
Other Infection Control Breaches	25	6%
Other	27	6%
Total (454)	478	

Note: The total number of events is greater than the number of responses, because for each response multiple event types can be selected.


Performance Measure (E25): COVID-19 Outbreaks and Response Consultations in Healthcare Settings

Table 11: Number of Possible COVID-19 Outbreaks and Response Consultations in Healthcare Settings, January 1, 2020 – July 31, 2020

Setting Type	Number of Possible COVID-19 Outbreaks by setting type	Possible Outbreaks with Any Response Consultation
SNF	9,435 (52%)	7,775 (82%)
Assisted Living Facility	4,703 (26%)	3,446 (73%)
Other Setting	3,373 (18%)	2,420 (72%)
Acute Care Hospital	574 (3%)	431 (75%)
LTACH	111 (<1%)	94 (82%)
Outpatient Dialysis	75 (<1%)	67 (89%)
Critical Access Hospital	37 (<1%)	26 (70%)
Total	18,308 (100%)	14,259 (78%)
Total Aug 1, 2020 – Dec 31, 2020	34,991 (100%)	24,825 (71%)


Prevention and Intervention Strategies (PM4)

Figure 9: Prevention-Based Onsite Infection Control Assessments (Non-COVID-19), August 1, 2019 – July 31, 2020



Prevention and Intervention Strategies (E24): Number of Facilities that Received Prevention-Based Healthcare Infection Control Assessments for COVID-19 by Setting


January 1, 2020 – July 31, 2020



Performance Measure (E23): Staff Capacity to Conduct Infection Control Assessments as of July 31, 2020

Figure 13: Distribution of Workplace for the Health Department Staff (N=415)


Total number of HD staff capable of conducting IC assessments: 415



HD Staff Capable of Conducting Healthcare Infection Control Assessments as of December 31, 2020: 681


Performance Measure (E23): Staff Capacity to Conduct Infection Control Assessments as of July 31, 2020

DISTRIBUTION OF FUNDING SOURCES (N=415)



TOP 5 OTHER FUNDING SOURCES (N = 192)

"Other" Funding Mechanism	Number of Staff
State-funded	54
Public Health Emergency Preparedness (PHEP) Cooperative Agreement	21
Facility Regulation	15
Local Funding	15
ELC other than G1	13



HAI/AR Programs Progress Report Preliminary Jurisdiction Specific Report

2019–2020 Report

Period of Performance: August 1, 2019–December 31, 2020

CDC/DDID/NCEZID/DHQP

Performance Measure (PM)		August 1, 2019 - July 31, 2020 (ELC Year 1 Final)							August 1, 2020 - December 31, 2020 (ELC Year 2 Interim)						
		Jurisdiction	18 comparator HAI/AR Programs with similar population size (580,000–2,320,000)*			HAI/AR Programs Nationwide			Jurisdiction	18 comparator HAI/AR Programs with similar population size (580,000–2,320,000)*			HAI/AR Programs Nationwide		
			Total	Mean	Median	Range	Mean	Median		Range	Total	Mean	Median	Range	Mean
Surveillance, Detection and Response															
PM1†	No. of clinical laboratories engaged to improve testing	76	26	15	0–92	42	31	0–150	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	Percentage of clinical laboratories engaged to improve testing	71%	71%	89%	0–100%	63%	74%	0–100%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PM2†	No. of AR Containment Responses or AR Consultations to novel or target MDROs	5	9	4	0–47	68	27	0–468	1	2	1	0–11	25	7	0–248
	No. of AR Containment Responses to novel or target MDROs (includes onsite and/or remote infection control assessment and/or colonization screening)	4	2	1	0–4	7	4	0–57	0	1	0	0–2	3	1	0–17
	No. of AR Consultations to novel or target MDROs (HD consulted via email and/or phone only and no assessment and screening conducted)	1	7	1	1–44	60	19	0–457	1	2	1	0–10	23	4	0–243
PM3	No. of other HAI/AR (non-AR) responses (COVID-19 response reported separately. See E25 below)	5	3	2	1–8	8	4	1–52	0	1	0	0–2	2	1	0–12
Prevention and Intervention Strategies															
PM4	No. of facilities that received prevention-based onsite infection control assessments	11	12	2	0–133	10	2	0–133	0	1	0	0–1	1	0	0–26
PM5	No. of facilities engaged by HDs to implement antibiotic stewardship	20	6	1	0–30	62	7	0–1,012	156	17	0	0–156	69	0	0–1,623
Communication, Coordination and Partnerships															
PM6†	Status of HAI/AR plan	Updates underway	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PM7†	No. of healthcare setting inventories updated (out of 10 setting types)	6	5	6	0–9	6	7	0–10	N/A	N/A	N/A	N/A	N/A	N/A	N/A

* See Page 3 for a map of health departments included in this comparison group.

† Performance measures listed as N/A are collected only once annually at the end of the period. These data are not available mid-period. Reporting of remote infection control assessment data began August 2020 and is not available for prior reporting periods.

‡ Refer to the Appendix A for an explanation of how AR containment responses and AR consultations were calculated.

Limitations

- There are limitations to using performance measures alone to evaluate a program or project.
- Under-reporting due to ongoing COVID-19 response
- Definitions of what constitutes a response are challenging

Final Notes

- During the 2019–2020 program year, the primary focus for HD shifted toward COVID-19 prevention and response activities,
- In addition to the surge of COVID-19 activities, HAI/AR Programs continued to respond to urgent HAI and AR threats
- Continue to monitor the progress made the HAI/AR programs
- Forthcoming: HAI/AR Programs Progress Report 2020-2021!

Acknowledgements

- HAI/AR Programs at the state, local, and territorial health departments
- HAI/AR Performance measures work-group
- CDC subject matter experts
- Field Support Team